Answers are grounded in this paper and cite their sources.
Preclinical study reveals that M18-China GP38 elicits cross-reactive immunity in mice, indicating potential value as a component in broadly protective Crimean-Congo hemorrhagic fever vaccines.
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne, negative-strand RNA virus that causes outbreaks of lethal hemorrhagic fever. No approved vaccines or specific antiviral treatments are available. CCHFV glycoprotein GP38 is an integral component of the pre-fusion glycoprotein entry complex, plays roles in viral pathogenesis, and is a key target of antibody-mediated protection. Herein, we investigated the hypothesis that recombinant GP38 itself could elicit protection against divergent CCHFV isolates/strains in an animal model. Accordingly, we generated GP38 immunogens from six CCHFV clades and showed that GP38 from the isolate M18-China induces a broad immunological response in mice despite its lower amino acid sequence similarity to other isolates. We identified sequences in M18-China GP38 associated with this immunological breadth and evaluated it as a vaccine candidate. Although M18-China GP38 was not protective in isolation, our findings warrant further exploration of its utility as one component of a broadly protective CCHFV vaccine.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: